uniQure’s (QURE) “Buy” Rating Reaffirmed at Chardan Capital

Chardan Capital reissued their buy rating on shares of uniQure (NASDAQ:QURE) in a report issued on Monday,Benzinga reports. They currently have a $35.00 price objective on the biotechnology company’s stock.

Several other analysts have also recently weighed in on QURE. Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a report on Saturday, August 2nd. HC Wainwright reiterated a “buy” rating and issued a $70.00 price target on shares of uniQure in a report on Friday, September 5th. Guggenheim reiterated a “buy” rating and issued a $28.00 price target on shares of uniQure in a report on Monday, May 12th. Cantor Fitzgerald set a $47.00 price objective on uniQure in a research report on Wednesday, July 30th. Finally, Mizuho raised uniQure from a “neutral” rating to an “outperform” rating and set a $30.00 price objective for the company in a research report on Thursday, August 14th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, uniQure currently has an average rating of “Buy” and a consensus price target of $37.45.

uniQure Stock Performance

NASDAQ:QURE opened at $17.48 on Monday. The stock has a market cap of $959.13 million, a P/E ratio of -4.46 and a beta of 0.14. The firm’s fifty day simple moving average is $15.19 and its 200 day simple moving average is $13.90. uniQure has a twelve month low of $4.45 and a twelve month high of $19.18. The company has a quick ratio of 9.98, a current ratio of 9.98 and a debt-to-equity ratio of 1.53.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.20. The business had revenue of $5.26 million for the quarter, compared to analysts’ expectations of $5.00 million. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. As a group, research analysts predict that uniQure will post -3.75 EPS for the current year.

Insider Buying and Selling at uniQure

In other uniQure news, Director Rachelle Suzanne Jacques sold 2,112 shares of the firm’s stock in a transaction on Friday, June 20th. The stock was sold at an average price of $14.45, for a total transaction of $30,518.40. Following the completion of the transaction, the director owned 28,346 shares of the company’s stock, valued at approximately $409,599.70. This trade represents a 6.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Robert Gut sold 3,336 shares of the firm’s stock in a transaction on Friday, June 20th. The shares were sold at an average price of $14.45, for a total value of $48,205.20. Following the transaction, the director directly owned 56,879 shares of the company’s stock, valued at $821,901.55. This represents a 5.54% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,144 shares of company stock valued at $322,426. Company insiders own 4.79% of the company’s stock.

Hedge Funds Weigh In On uniQure

Large investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC raised its position in shares of uniQure by 358.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 5,538 shares during the last quarter. Mraz Amerine & Associates Inc. purchased a new position in shares of uniQure in the 1st quarter worth about $106,000. KLP Kapitalforvaltning AS purchased a new position in shares of uniQure in the 2nd quarter worth about $117,000. Teacher Retirement System of Texas purchased a new position in shares of uniQure in the 2nd quarter worth about $151,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in shares of uniQure in the 1st quarter worth about $152,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.